The latest financial statement is for the quarter ending 2026-01-31.
| Cash Flow | 2026-01-31 |
|---|---|
| Net (loss) income | -54,853 |
| Interest expenses | 0 |
| Share-based compensation | 0 |
| Inventories | 86,189 |
| Accounts receivable | -262,509 |
| Advances to vendors | -158,802 |
| Other current assets | 4,583 |
| Accounts payable | 108,978 |
| Accrued expenses and other current liabilities | 21,066 |
| Income tax payable | -19,636 |
| Net cash provided by (used in) operating activities | 386,094 |
| Interest paid | 0 |
| Proceeds from a related party | 0 |
| Net cash provided by financing activity | 0 |
| Net change in cash | 386,094 |
| Cash, beginning of period | 782,810 |
| Cash, end of period | 1,168,904 |
VitaNova Life Sciences Corp (VNOV)
VitaNova Life Sciences Corp (VNOV)